Aabakken L, Bjørnbeth B A, Weberg R, Viksmoen L, Larsen S, Osnes M
Medical Department, Ullevål Hospital, Oslo, Norway.
Aliment Pharmacol Ther. 1990 Jun;4(3):295-303. doi: 10.1111/j.1365-2036.1990.tb00474.x.
Eighteen healthy volunteers were included in a cross-over, double-blind study where 500 mg naproxen b.d. was given for 1 week with 20 mg famotidine b.d., 40 mg nocte or placebo. Endoscopic evaluation of the gastroduodenal mucosa was performed before and after each treatment period, with separate evaluation of the mid- and distal duodenum. 51Cr-EDTA-permeability tests were done to study effects on the mid- and distal gut, and, in addition, symptom registration was performed. The mucosal damage was significant in all treatment periods, and a statistically significant reduction was seen with 20 mg famotidine b.d. for erosive lesions in the stomach/duodenal bulb region as well as for the sum of damage score in the mid- and distal duodenum. The reduction was considerable in a few subjects with extensive duodenal damage. The reduction was considerable in a few subjects with extensive duodenal damage. Intestinal permeation increased significantly in all periods, and was not reduced by famotidine. Symptoms were modest and equal in all periods.
18名健康志愿者参与了一项交叉双盲研究，其中500毫克萘普生每日两次给药1周，同时分别给予20毫克法莫替丁每日两次、40毫克每晚一次或安慰剂。在每个治疗期前后进行胃十二指肠黏膜的内镜评估，并对十二指肠中部和远端进行单独评估。进行51铬-乙二胺四乙酸（51Cr-EDTA）通透性测试以研究对肠道中部和远端的影响，此外还进行症状记录。在所有治疗期黏膜损伤均显著，对于胃/十二指肠球部区域的糜烂性病变以及十二指肠中部和远端损伤评分总和，每日两次给予20毫克法莫替丁可使损伤有统计学意义的显著减轻。在一些十二指肠损伤广泛的受试者中减轻程度相当可观。在所有时期肠道通透性均显著增加，且未被法莫替丁降低。各时期症状均较轻且无差异。
